José Ramón Lago-Quinteiro, Francisco Reyes-Santias, Manel Antelo, Vicent Caballer-Tarazona, José Luis Martinez-Sande, Javier Garcia-Seara, Moisés Rodriguez-Manero, Jose Ramon Gonzalez-Juanatey
{"title":"Single-chamber pacemakers: with or without leads? Cost-effectiveness and cost-utility analyses.","authors":"José Ramón Lago-Quinteiro, Francisco Reyes-Santias, Manel Antelo, Vicent Caballer-Tarazona, José Luis Martinez-Sande, Javier Garcia-Seara, Moisés Rodriguez-Manero, Jose Ramon Gonzalez-Juanatey","doi":"10.1080/07853890.2025.2512108","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The evolution in pacemaker technologies has led to improvements in size, weight, functionality, and durability, even as the battery and electrode-based structural configuration has remained essentially the same.</p><p><strong>Objective: </strong>To compare the cost-effectiveness and cost-utility of conventional and leadless pacemakers.</p><p><strong>Material and methods: </strong>We conducted a retrospective observational study of 403 patients randomly implanted with a conventional or leadless pacemaker (1 June 2015-31 January 2020) in the Hospital-University Complex of Santiago de Compostela (Galicia, NW Spain).</p><p><strong>Results: </strong>Conventional and leadless pacemakers were implanted in 244 and 159 patients, respectively. Leadless pacemakers were superior to the conventional pacemakers in terms of both cost-effectiveness and cost-utility, with incremental cost-effectiveness ratios of 6,263.38 euros per gained life year and of 5,210.71 euros per quality-adjusted life year, respectively.</p><p><strong>Conclusions: </strong>Leadless pacemakers have fewer complications than conventional pacemakers and, although the device itself is more expensive, the leadless pacemaker is more cost-effective in around 90% of cases.</p>","PeriodicalId":93874,"journal":{"name":"Annals of medicine","volume":"57 1","pages":"2512108"},"PeriodicalIF":0.0000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12123902/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/07853890.2025.2512108","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/29 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: The evolution in pacemaker technologies has led to improvements in size, weight, functionality, and durability, even as the battery and electrode-based structural configuration has remained essentially the same.
Objective: To compare the cost-effectiveness and cost-utility of conventional and leadless pacemakers.
Material and methods: We conducted a retrospective observational study of 403 patients randomly implanted with a conventional or leadless pacemaker (1 June 2015-31 January 2020) in the Hospital-University Complex of Santiago de Compostela (Galicia, NW Spain).
Results: Conventional and leadless pacemakers were implanted in 244 and 159 patients, respectively. Leadless pacemakers were superior to the conventional pacemakers in terms of both cost-effectiveness and cost-utility, with incremental cost-effectiveness ratios of 6,263.38 euros per gained life year and of 5,210.71 euros per quality-adjusted life year, respectively.
Conclusions: Leadless pacemakers have fewer complications than conventional pacemakers and, although the device itself is more expensive, the leadless pacemaker is more cost-effective in around 90% of cases.